• Explore /
  • Poster
  • / Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Ulka Vaishampayan

Ulka N. Vaishampayan

University of Michigan Cancer Center, Detroit, MI

Ulka N. Vaishampayan , Marianne Keessen , Neal D. Shore , Elisabeth I. Heath , Robert Dreicer , Tomas Buchler , Péter Ferenc Árkosy , Tibor Csoszi , Pawel J. Wiechno , Evgeny Kopyltsov , Denis Kholtobin , Sergey Orlov , Aleander Nosov , Sergey Varlamov , Nicholas J. Vogelzang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04028388

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 117)

DOI

10.1200/JCO.2022.40.6_suppl.117

Abstract #

117

Poster Bd #

F8

Abstract Disclosures

Similar Posters

First Author: Ulka N. Vaishampayan

First Author: Ulka N. Vaishampayan

First Author: Ulka N. Vaishampayan

First Author: Daniel Petrylak